Biotech Values

[DewDiligence]

ESPR—…do you see an opportunity to buy shares at a 20% discount or, given the news from AMGN and REGN, is better to stay away?

I’m staying away. The crux of EPSR’s business plan has been to finagle FDA/EMA approval without having to run (and pay for) a CVOT. After the PCSK9 panels, accomplishing this task seems less likely.